These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32141890)

  • 1. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus.
    Maepa MB; Jacobs R; van den Berg F; Arbuthnot P
    Curr Opin HIV AIDS; 2020 May; 15(3):200-207. PubMed ID: 32141890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.
    Ely A; Moyo B; Arbuthnot P
    Mol Ther; 2016 Apr; 24(4):671-7. PubMed ID: 26916283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection.
    Ely A; Singh P; Smith TS; Arbuthnot P
    Adv Drug Deliv Rev; 2021 Jan; 168():134-146. PubMed ID: 32485207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
    Revill P; Locarnini S
    Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach.
    Singh P; Kairuz D; Arbuthnot P; Bloom K
    World J Gastroenterol; 2021 Jun; 27(23):3182-3207. PubMed ID: 34163105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
    Kennedy EM; Kornepati AV; Cullen BR
    Antiviral Res; 2015 Nov; 123():188-92. PubMed ID: 26476375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and Prospects of Anti-HBV Gene Therapy Development.
    Maepa MB; Roelofse I; Ely A; Arbuthnot P
    Int J Mol Sci; 2015 Jul; 16(8):17589-610. PubMed ID: 26263978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting Hepatitis B Virus: Challenges of Curative Therapies.
    Hu J; Protzer U; Siddiqui A
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
    Ely A; Arbuthnot P
    Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.
    Xia Y; Guo H
    Antiviral Res; 2020 Aug; 180():104824. PubMed ID: 32450266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
    Sheraz M; Cheng J; Tang L; Chang J; Guo JT
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric
    Smith T; Singh P; Chmielewski KO; Bloom K; Cathomen T; Arbuthnot P; Ely A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
    Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
    mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
    Nassal M
    Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the study of hepatitis B virus covalently closed circular DNA.
    Ji M; Hu K
    Virol Sin; 2017 Dec; 32(6):454-464. PubMed ID: 29280054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.